Verilogue, Inc.

Verilogue, Inc. provides analytics focused on patient experience by capturing real-world interactions between patients and healthcare providers, enabling pharmaceutical and healthcare organizations to enhance treatment adherence and patient engagement. Founded in 2005 in Philadelphia, US, Verilogue specializes in analyzing physician-patient conversations to derive actionable healthcare insights. The company was acquired by Publicis Groupe in December 2013, with specific financial details undisclosed.

The firm has engaged in two deals to date and raised a total of USD 4. 00 mn, with its latest funding round being a USD 4. 00 mn investment from Edison Partners. Verilogue specializes in providing comprehensive insights into the patient experience by capturing and analyzing real-world interactions between patients and healthcare providers.

The company leverages the world’s largest collection of in-office physician-patient conversations to develop advanced research methodologies that yield actionable insights for the healthcare industry. Its offerings are designed to support pharmaceutical manufacturers and healthcare organizations in understanding the complexities of treatment adherence and patient engagement. Verilogue's services are utilized primarily by pharmaceutical companies, such as Pfizer, and are aimed at enhancing brand growth through improved patient compliance and healthcare outcomes. The company operates within key markets in North America, Europe, and potentially extends its insights to clients in Asia-Pacific regions.

Verilogue generates revenue through a business-to-business model, primarily engaging with pharmaceutical manufacturers and healthcare organizations. The transaction structure typically involves subscription-based access to its linguistic data and analytical services, enabling clients to leverage patient insights for marketing and strategic planning. Clients may enter into partnerships for long-term engagements that facilitate continuous access to Verilogue’s extensive database and ongoing updates regarding patient-provider interactions. The firm’s flagship offerings center around tailored research solutions that address specific client challenges, thus underscoring the personalized nature of its services.

Specific pricing details for these services and subscription plans are determined based on client needs and project scopes, allowing for flexibility in service delivery. Verilogue's strategy for future growth includes exploring new product developments and enhancements to its existing analytics platforms, with plans to expand its services into additional geographic regions, particularly targeting more clients in Asia-Pacific by 2015. The recent funding of USD 4. 00 mn will help support these initiatives and facilitate broader market penetration, as well as ongoing innovation in their product offerings.